Jefferies Raises Roivant Sciences Price Target to $52 on Trials

Jefferies raised its price target on Roivant Sciences (NASDAQ:ROIV) to $52 from $42 while maintaining a Buy rating following positive Phase II clinical trial results for its experimental treatment mosliciguat, according to Investing.com. The upward revision reflects stronger data than expected in pulmonary hypertension and expands the company's projected revenue trajectory compared to prior analyst models.

Roivant Sciences shares trade at $41.22, reflecting a 171% gain over the past year that places the equity near its 52-week high. This performance outpaces broader biotechnology benchmarks as institutional interest shifts toward late-stage clinical readouts.

Clinical Trial Data and Efficacy Metrics

The price target increase stems from Phase II clinical trial results evaluating mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease. According to the trial findings cited by Jefferies, the therapy achieved statistical significance at 16 weeks for both pulmonary vascular resistance and six-minute walk distance measures, with therapeutic benefits continuing through 24 weeks.

Pulmonary hypertension associated with interstitial lung disease is a severe condition characterized by high blood pressure in the lung arteries coupled with lung tissue scarring. The primary efficacy endpoints measured, which are pulmonary vascular resistance and walking distance, serve as standard indicators of functional capacity and hemodynamic improvement in regulatory evaluations.

Revenue Projections and Peak Sales Estimates

Beyond the immediate Phase II readout, investment analysts have broadened their financial models for the drug. Jefferies estimates that mosliciguat holds peak sales potential exceeding $5 billion across multiple prospective indications.

Those expanded indications include idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Securing approvals across these additional fibrotic lung diseases would broaden the addressable patient population beyond pulmonary hypertension alone, altering the long-term revenue profile for the biopharmaceutical firm.

Market Position and Next Steps for Roivant

For Roivant Sciences, the positive trial results validate the company's business model of acquiring and advancing clinical-stage assets through dedicated subsidiary companies. As management prepares for subsequent late-stage development phases, the focus shifts toward designing pivotal registration trials capable of securing regulatory approval in major markets.